dose escalation is the most under-discussed thing on this board
Something I keep coming back to: dose escalation is the most under-discussed thing on this board. The early fullness profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression. Watched heart rate on a wearable across twelve weeks because the threads said to. It…
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
Are you tracking heart rate at all?
the energy-expenditure story is mechanistically interesting and clinically unproven
the phase 2 numbers were striking and they were also 48 weeks in a small population
comparing reta phase 2 to sema phase 3 is comparing different things
heart rate is the thing people report watching